公开(公告)号：US20210060210A1

公开(公告)日：2021-03-04

申请号：US16982179

申请日：2019-03-18

Applicant: Kyoto University ,  Takeda Pharmaceutical Company Limited

Inventor： Taro TOYODA ,  Taisuke MOCHIDA ,  Yutaka TANOUE ,  Ryo ITO ,  Koya KIMOTO ,  Yusuke KOIKE ,  Hikaru UENO

IPC: A61L27/38 ,  A61K9/06 ,  A61K47/36 ,  A61L27/36 ,  A61P3/10 ,  A61L27/54 ,  A61L27/20 ,  A61K35/39 ,  C12N5/071

Abstract: An object of the present invention is to provide a method for removing highly proliferative Ki67-positive cells co-present in insulin-secreting cells obtained by differentiation induction. A method for producing an insulin-producing cell population or a pancreatic beta cell population containing less than 3% of Ki67-positive cells, comprising: embedding an endocrine progenitor cell population or a cell population at a later stage of differentiation into a gel containing alginic acid; and differentiating the cell population.

公开(公告)号：US20210353686A1

公开(公告)日：2021-11-18

申请号：US17277406

申请日：2019-09-18

Applicant: Takeda Pharmaceutical Company Limited ,  Kyoto University

Inventor： Ryo ITO ,  Noriko YAMAZOE ,  Hideyuki HIYOSHI ,  Taisuke MOCHIDA ,  Hikaru UENO ,  Kensuke SAKUMA ,  Junji YAMAURA ,  Hirokazu MATSUMOTO ,  Taro TOYODA ,  Shuhei KONAGAYA

IPC: A61K35/39 ,  C12N5/071 ,  A61P3/10 ,  A61P5/50

Abstract: The purpose of the present invention is to provide a novel method for making it possible to efficiently induce/produce endocrine cells from pluripotent stem cells. Insulin-producing cells including cells that are insulin-positive and NKX6.1-positive cells in a ratio of at least 30% and cells that are insulin-positive and NKX6.1-negative in a ratio of more than 15%.

公开(公告)号：US20180327719A1

公开(公告)日：2018-11-15

申请号：US15760523

申请日：2016-09-16

Applicant: Kyoto University

Inventor： Kenji OSAFUNE ,  Taro TOYODA ,  Azuma KIMURA

IPC: C12N5/071

CPC classification number: C12N5/0676 ,  C12N5/10 ,  C12N2501/11 ,  C12N2501/117 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/41 ,  C12N2501/727 ,  C12N2506/03

Abstract: Provided is a method for generating pancreatic bud cells, comprising the step of culturing PDX1+/NKX6.1− cells in a medium comprising KGF, EGY, a DMP inhibitor and an Akt inhibitor. The cells may be cultured under adherent culture conditions. PDX1+/NKX6.1− cells may be induced from pluripotent stem cells in vitro. The method of this application makes it possible to generate pancreatic bud cells from pluripotent stem cells.

公开(公告)号：US20210292708A1

公开(公告)日：2021-09-23

申请号：US17265364

申请日：2019-08-02

Applicant: Kyoto University ,  Takeda Pharmaceutical Company Limited

Inventor： Noriko YAMAZOE ,  Hideyuki HIYOSHI ,  Taro TOYODA

IPC: C12N5/00

Abstract: An object of the present invention is to provide a novel approach that enables definitive endoderm cells or insulin-producing cells to be efficiently induced and/or manufactured from pluripotent stem cells. The present invention provides a method for producing definitive endoderm cells from pluripotent stem cells, comprising subjecting pluripotent stem cells to first culture in a differentiation-inducing medium in which insulin acts and subsequently to second culture in a differentiation-inducing medium in which insulin does not act.

公开(公告)号：US20210254014A1

公开(公告)日：2021-08-19

申请号：US17049218

申请日：2019-04-22

Applicant: Kyoto University ,  Takeda Pharmaceutical Company Limited

Inventor： Noriko YAMAZOE ,  Hideyuki HIYOSHI ,  Taisuke MOCHIDA ,  Ryo ITO ,  Taro TOYODA ,  Azuma KIMURA

IPC: C12N5/071 ,  A61K35/39

Abstract: The present invention relates to a method for producing an insulin-producing cell population or a pancreatic β cell population having the reduced number of Ki67-positive cells, comprising treating a population of endocrine progenitor cells or cells at a later stage of differentiation with an FGFR1 inhibitor.

公开(公告)号：US20190390169A1

公开(公告)日：2019-12-26

申请号：US16490394

申请日：2018-03-02

Applicant: Kyoto University ,  Takeda Pharmaceutical Company Limited

Inventor： Kenji OSAFUNE ,  Taro TOYODA ,  Shiro TAKEKAWA ,  Goshi NAKAMURA ,  Ryo ITO

IPC: C12N5/071 ,  A61K35/545

Abstract: The present invention relates to a method for producing pancreatic progenitor cells from pluripotent stem cells. More specifically, the present invention relates to a method for producing pancreatic progenitor cells, comprising causing the action of a factor having the inhibitory activity for cyclin-dependent kinase 8 and/or cyclin-dependent kinase 19 (hereinafter, also abbreviated to CDK8/19).

公开(公告)号：US20170175082A1

公开(公告)日：2017-06-22

申请号：US15311759

申请日：2015-05-20

Applicant: Kyoto University

Inventor： Kenji OSAFUNE ,  Taro TOYODA

IPC: C12N5/071 ,  A61K35/39

CPC classification number: C12N5/0676 ,  A61K35/39 ,  C12N2501/11 ,  C12N2501/117 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/41 ,  C12N2501/727 ,  C12N2501/999 ,  C12N2506/02 ,  Y02A20/402

Abstract: Provided is a method for generating pancreatic bud cells, having the step of culturing PDX1+/NKX6.1− cells in a medium containing KGF, EGF and a BMP inhibitor. The culturing step may be performed in suspension cultures or in adherent cultures. When the cells are cultured in adherent cultures, the cells may be cultured in a medium further containing a ROCK inhibitor or a nonmuscle myosin II inhibitor.